CA3118542A1 - Cdcp1-targeted therapies - Google Patents
Cdcp1-targeted therapies Download PDFInfo
- Publication number
- CA3118542A1 CA3118542A1 CA3118542A CA3118542A CA3118542A1 CA 3118542 A1 CA3118542 A1 CA 3118542A1 CA 3118542 A CA3118542 A CA 3118542A CA 3118542 A CA3118542 A CA 3118542A CA 3118542 A1 CA3118542 A1 CA 3118542A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- cdcp1
- cancer
- seq
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/915—Fusion polypeptide containing a motif for post-translational modification containing a motif for acylation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862758442P | 2018-11-09 | 2018-11-09 | |
| US62/758,442 | 2018-11-09 | ||
| PCT/US2019/060276 WO2020097336A1 (en) | 2018-11-09 | 2019-11-07 | Cdcp1-targeted therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3118542A1 true CA3118542A1 (en) | 2020-05-14 |
Family
ID=70612233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3118542A Pending CA3118542A1 (en) | 2018-11-09 | 2019-11-07 | Cdcp1-targeted therapies |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12371507B2 (https=) |
| EP (1) | EP3876988A4 (https=) |
| JP (1) | JP7440509B2 (https=) |
| CN (1) | CN113382750B (https=) |
| AU (1) | AU2019376078B2 (https=) |
| CA (1) | CA3118542A1 (https=) |
| MX (1) | MX2021005377A (https=) |
| WO (1) | WO2020097336A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102225039B1 (ko) * | 2018-12-17 | 2021-03-10 | 한국과학기술원 | Cd8+ 메모리 t 세포 매개성 질환의 예방 또는 치료용 약학 조성물 |
| JP7623705B2 (ja) * | 2019-12-27 | 2025-01-29 | 株式会社カイオム・バイオサイエンス | 抗ｃｄｃｐ１抗体 |
| WO2023134715A1 (zh) * | 2022-01-12 | 2023-07-20 | 中国医学科学院阜外医院 | 心肌细胞的分离试剂和分离方法 |
| CA3259098A1 (en) * | 2022-06-20 | 2025-04-18 | Sichuan Huiyu Seacross Pharmaceutical Technology Co., Ltd. | ANTIBODIES AND THEIR USES |
| CA3261603A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | ANTIBODY-DRUG CONJUGATES |
| AU2024248799A1 (en) * | 2023-03-31 | 2025-10-23 | Daiichi Sankyo Company, Limited | Combination of anti-CDH6 antibody-drug conjugate and HIF-2alpha inhibitor |
| WO2025226017A1 (ko) * | 2024-04-22 | 2025-10-30 | 주식회사 노벨티노빌리티 | 신규 항-cdcp1 인간화 항체 및 이의 용도 |
| WO2025252137A1 (zh) * | 2024-06-06 | 2025-12-11 | 荣昌生物制药(烟台)股份有限公司 | 一种抗体药物偶联物 |
| WO2025262641A1 (en) | 2024-06-19 | 2025-12-26 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
| WO2026078443A1 (en) | 2024-10-11 | 2026-04-16 | Pheon Therapeutics Ltd. | Antibody drug conjugates that bind cdcp1 and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6551795B1 (en) | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| US20040191260A1 (en) * | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| AU2003207459A1 (en) | 2002-01-03 | 2003-07-24 | The Scripps Research Institute | Cancer-associated epitope |
| US20080008719A1 (en) * | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
| US8716451B2 (en) * | 2005-01-12 | 2014-05-06 | Kyowa Hakko Kirin Co., Ltd | Stabilized human IgG2 and IgG3 antibodies |
| WO2007005502A2 (en) | 2005-06-30 | 2007-01-11 | Applera Corporation | Methods and compositions for treating diseases targeting cdcp1 |
| PT2594590E (pt) * | 2007-12-14 | 2015-01-14 | Bristol Myers Squibb Co | Moléculas de ligação ao recetor humano ox40 |
| US7951370B2 (en) | 2008-03-12 | 2011-05-31 | Imclone Llc | Anti-TYRP1 antibodies |
| TWI412375B (zh) * | 2009-08-28 | 2013-10-21 | Roche Glycart Ag | 人類化抗ｃｄｃｐ１抗體 |
| TW201113037A (en) * | 2009-08-28 | 2011-04-16 | Hoffmann La Roche | Antibodies against CDCP1 for the treatment of cancer |
| EP4012714A1 (en) * | 2010-03-23 | 2022-06-15 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| US9127056B2 (en) | 2011-10-17 | 2015-09-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II) |
| PT3134127T (pt) | 2014-04-25 | 2020-04-09 | Rinat Neuroscience Corp | Conjugados de anticorpo-fármaco com alta carga de fármaco |
| KR20170075778A (ko) | 2014-10-27 | 2017-07-03 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 항-tim-3 항체 |
| RU2757314C2 (ru) | 2016-01-22 | 2021-10-13 | Мерк Шарп И Доум Корп. | Антитела против фактора свертывания xi |
| EP3554544A4 (en) * | 2016-12-16 | 2020-07-29 | Bluefin Biomedicine, Inc. | ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE |
-
2019
- 2019-11-07 US US17/292,257 patent/US12371507B2/en active Active
- 2019-11-07 AU AU2019376078A patent/AU2019376078B2/en active Active
- 2019-11-07 CA CA3118542A patent/CA3118542A1/en active Pending
- 2019-11-07 CN CN201980084226.5A patent/CN113382750B/zh active Active
- 2019-11-07 JP JP2021525787A patent/JP7440509B2/ja active Active
- 2019-11-07 EP EP19883243.8A patent/EP3876988A4/en active Pending
- 2019-11-07 WO PCT/US2019/060276 patent/WO2020097336A1/en not_active Ceased
- 2019-11-07 MX MX2021005377A patent/MX2021005377A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021005377A (es) | 2021-09-14 |
| EP3876988A1 (en) | 2021-09-15 |
| CN113382750A (zh) | 2021-09-10 |
| WO2020097336A1 (en) | 2020-05-14 |
| JP2022507294A (ja) | 2022-01-18 |
| AU2019376078A1 (en) | 2021-06-03 |
| CN113382750B (zh) | 2025-05-09 |
| US20220119545A1 (en) | 2022-04-21 |
| AU2019376078B2 (en) | 2026-02-12 |
| US12371507B2 (en) | 2025-07-29 |
| EP3876988A4 (en) | 2022-11-09 |
| JP7440509B2 (ja) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12371507B2 (en) | CDCP1 antibodies and antibody drug conjugates | |
| US11873339B2 (en) | Anti-C10orf54 antibodies and uses thereof | |
| US10414823B2 (en) | Anti-C10orf54 antibodies and uses thereof | |
| US10556959B2 (en) | Anti-CD39 antibodies and uses thereof | |
| JP7383682B2 (ja) | 抗ｅｄｂ抗体および抗体－薬物コンジュゲート | |
| JP2020502271A (ja) | 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 | |
| RU2819627C1 (ru) | Антитела к c10orf54 и их применения | |
| BR122024006481A2 (pt) | Conjugados de anticorpo-fármaco, composição farmacêutica e seus usos, processo para a produção de um conjugado de anticorpo-fármaco, anticorpo, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo e método para detectar domínio b extra de fibronectina | |
| BR112019007760B1 (pt) | Conjugados de anticorpo-fármaco, composição farmacêutica, ácido nucleico, vetor, processo para a produção do conjugado de anticorpofármaco e uso do conjugado de anticorpo-fármaco |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220923 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241101 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241101 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241101 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250516 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250916 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251031 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251031 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251121 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251121 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251121 |